Navigation Links
New 'implanted contacts' designed to fix nearsightedness

UT Southwestern Medical Center ophthalmologists will be the first in the area to insert a new type of implanted lens to fix nearsightedness.

"Think of it as a contact lens inside your eye," said Dr. Wayne Bowman, who is inserting the new implantable collamer lens, or ICL, today for the first time at UT Southwestern University Hospitals.

The ICL can replace or reduce the need for glasses by permanently placing the specially fitted artificial lens in front of the eye's natural lens, rather than replacing the natural lens as other implanted lens do, said Dr. Bowman, professor of ophthalmology.

The lens, made of a special collamer material, corrects moderate to severe nearsightedness, known as myopia, by bending light rays to improve blurry distance vision without the need for glasses or contacts.

Dr. Bowman said the lens currently is approved only for nearsightedness, but it may eventually be available for farsightedness and astigmatism. It has been used for nearsightedness for several years in Europe and was approved by the Food and Drug Administration in December.

According to the FDA, a clinical study of 294 implanted patients showed that 95 percent ?279 patients ?had 20/40 or better vision, which is considered the standard needed for an unrestricted driver's license. And 59 percent ?almost 175 patients ?had 20/20 or better vision after three years.

Ideal candidates are typically under 40 years of age and don't yet have presbyopia, which makes reading glasses necessary, and whose corrections are outside the parameters for routine laser procedures, said Dr. Steven Verity, associate professor of ophthalmology, who specializes in refractive corneal surgery.

Rather than reshaping the eye, as in laser surgery, or replacing the eye's natural lens, as with intraocular lenses, the collamer lens is inserted with a smaller incision. Th e lens is like a fixed contact, but it can be removed if need be.

The procedure, Dr. Bowman said, normally takes about 10 to 15 minutes, and the patient sees the improvement soon after.


Source:UT Southwestern Medical Center

Related biology news :

1. Medical molecules designed to respond to visible light that can penetrate tissue
2. Redesigned protein accelerates blood clotting
3. Intelligently designed molecular evolution
Post Your Comments:

(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: